4Q EARNINGS: Is 2015 Lilly's turning point?
This article was originally published in Scrip
Eli Lilly's revenue fell 15% to $19.6bn in 2014 from $23.1bn in 2013, largely due to patent expirations for two of its top-selling products, but the company believes that 2015 could be the year that things turn around and investors seemed to agree.
You may also be interested in...
Private Company Edition: The average exit from biopharma investments rose from $356.8m in 2019 to $520.6m in 2020, explaining the staggering $12bn invested in the industry during the first half of this year versus $17bn for all of last year. In recent VC deals, VelosBio’s $137m series B was the largest.
Neutralizing antibodies were seen in all 45 people injected across three dose levels in the first-in-human study. The middle dose of 100mcg will be tested in the company’s Phase III trial starting 27 July.
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.